These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16289997)

  • 21. Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
    Goris N; Maradei E; D'Aloia R; Fondevila N; Mattion N; Perez A; Smitsaart E; Nauwynck HJ; La Torre J; Palma E; De Clercq K
    Vaccine; 2008 Jun; 26(27-28):3432-7. PubMed ID: 18499310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of vaccination on foot and mouth disease virus transmission among dairy cows.
    Orsel K; de Jong MC; Bouma A; Stegeman JA; Dekker A
    Vaccine; 2007 Jan; 25(2):327-35. PubMed ID: 16949184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
    Maradei E; La Torre J; Robiolo B; Esteves J; Seki C; Pedemonte A; Iglesias M; D'Aloia R; Mattion N
    Vaccine; 2008 Dec; 26(51):6577-86. PubMed ID: 18835312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Some current questions regarding control of foot and mouth disease].
    Benndorf E
    Monatsh Veterinarmed; 1970 Mar; 25(6):215-8. PubMed ID: 5534896
    [No Abstract]   [Full Text] [Related]  

  • 25. [Non-vaccine regulation].
    Scholma-van der Perk D
    Tijdschr Diergeneeskd; 2001 Jul 15-Aug 1; 126(14-15):504. PubMed ID: 11510378
    [No Abstract]   [Full Text] [Related]  

  • 26. Foot-and-mouth disease vaccine potency testing: the influence of serotype, type of adjuvant, valency, fractionation method, and virus culture on the dose-response curve in cattle.
    Jamal SM; Bouma A; van den Broek J; Stegeman A; Chénard G; Dekker A
    Vaccine; 2008 Nov; 26(50):6317-21. PubMed ID: 18822336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Further evaluation of higher potency vaccines for early protection of cattle against FMDV direct contact challenge.
    Cox SJ; Parida S; Voyce C; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV
    Vaccine; 2007 Nov; 25(44):7687-95. PubMed ID: 17913309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Democratic state].
    ter Heide W
    Tijdschr Diergeneeskd; 2001 Jul 15-Aug 1; 126(14-15):504. PubMed ID: 11510377
    [No Abstract]   [Full Text] [Related]  

  • 29. [Point of view of KNMvD concerning foot and mouth disease marker vaccine].
    van Leeuwen JM
    Tijdschr Diergeneeskd; 2001 Sep; 126(17):585. PubMed ID: 11596520
    [No Abstract]   [Full Text] [Related]  

  • 30. Vaccination of mice with plasmids expressing processed capsid protein of foot-and-mouth disease virus--importance of dominant and subdominant epitopes for antigenicity and protection.
    Frimann TH; Barfoed AM; Aasted B; Kamstrup S
    Vaccine; 2007 Aug; 25(33):6191-200. PubMed ID: 17640782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Round table discussion about foot and mouth disease prevention and control. The goals and differences of opinion on how to get there].
    Vaarten J
    Tijdschr Diergeneeskd; 2001 Sep; 126(18):608-10. PubMed ID: 11596536
    [No Abstract]   [Full Text] [Related]  

  • 32. Foot and mouth disease: a revised policy is required.
    Bayry J; Kaveri SV
    J Clin Microbiol; 2001 Oct; 39(10):3808. PubMed ID: 11599518
    [No Abstract]   [Full Text] [Related]  

  • 33. Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle.
    Paton DJ; de Clercq K; Greiner M; Dekker A; Brocchi E; Bergmann I; Sammin DJ; Gubbins S; Parida S
    Vaccine; 2006 Oct; 24(42-43):6503-12. PubMed ID: 16872727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suitability of currently available vaccines for controlling the major transboundary diseases that afflict sub-Saharan Africa.
    Thomson G; Dungu B; Tounkara K; Vosloo W; Bastos A; Bidjeh K
    Dev Biol (Basel); 2003; 114():229-41. PubMed ID: 14677693
    [No Abstract]   [Full Text] [Related]  

  • 35. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde.
    Barteling SJ; Cassim NI
    Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experience in the eradication of foot-and-mouth disease].
    Veselov VI; Mukhin BS; Klykova LS
    Veterinariia; 1969 Sep; 9():16-7. PubMed ID: 5392422
    [No Abstract]   [Full Text] [Related]  

  • 37. Estimation of maternally acquired immunity in suckling mice to evaluate foot-and-mouth disease vaccine.
    Strobbe R; de Clercq K; Debecq J
    Arch Exp Veterinarmed; 1988 May; 42(3):410-3. PubMed ID: 2845880
    [No Abstract]   [Full Text] [Related]  

  • 38. [Comparative immunologic study on cattle of 2 strains of foot-and-mouth disease type O virus: O Flanders and O Spain 64].
    Fontaine J; Gayot G; Dubouclard C; Dhennin L; Roumiantzeff M; Terre J; Dhennin L
    Bull Off Int Epizoot; 1966; 65(11):2051-62. PubMed ID: 5994044
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of vaccines in South American foot-and-mouth disease eradication programmes.
    Saraiva V; Darsie G
    Dev Biol (Basel); 2004; 119():33-40. PubMed ID: 15742616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Expression of foot and mouth disease virus antigens in transgenic plants].
    Dus Santos MJ; Wigdorovitz A
    Rev Sci Tech; 2005 Apr; 24(1):175-87. PubMed ID: 16110887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.